HER2/neu 655 A > G polymorphism is associated with higher cardiotoxicity but not with less efficacy of trastuzumab, in HER2-positive breast cancer patients

Blancas, I.Rodriguez-Serrano, F.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/26021enHER2/neu 655 A > G polymorphism is associated with higher cardiotoxicity but not with less efficacy of trastuzumab, in HER2-positive breast cancer patientsconference outputopen access10.1016/j.annonc.2020.08.3001569-8041http://www.annalsofoncology.org/article/S0923753420402960/pdf573469100178